Abstract:Common cold viruses are leading triggers of asthma attacks, causing nearly two million hospitalizations per year and productivity losses approaching $40B. They also increase susceptibility to bacterial infections driving antibiotic use. Post-market clinical studies have questioned the efficacy of most over the counter (OTC) cough and cold ingredients against placebo in treating various symptoms. To our knowledge, only aspirin significantly improved overall illness severity compared to placebo and that was by about 25-30%. In this double-blind randomized placebo-controlled trial involving 157 participants, we sought to determine whether a throat spray containing a mucosal immune complex (MIC) (comprised of lysozyme, lactoferrin, and aloe) can increase the hereto reported efficacy of aspirin at reducing common cold symptoms. Previously published reports showed that the MIC can protect respiratory epithelia and lower inflammatory cytokines. Participants self-administered treatments (throat sprays every hour and tablets every four hours) and completed surveys at home over two days. Treatments included MIC spray mixed with 6mg aspirin + placebo tablet (Treatment 1), MIC spray + placebo tablet (Treatment 2), MIC spray + 325 mg aspirin tablet (Treatment 3). Participants included adult volunteers ages 21-66 (average 44), 54% female, 46% male, 46% African American, 8% Asian, 39% Caucasian, and 7% Hispanic, having common cold symptoms lasting less than two days. The main outcome measures included Sore Throat Pain Intensity (STPIS) 0-100 at 36 hours (primary endpoint) and Modified Jackson Score (MJS), a combination of eight cold symptoms (secondary endpoint). Both primary and secondary endpoints were met. Sore throat pain as measured by STPIS decreased 68-75% by 36 hours depending on treatment. Other symptoms such as nasal discharge, congestion, sneezing, cough, sore throat, and malaise as measured by MJS decreased 38-68% depending on treatment. In repeated measure within group analysis observing the same participants over multiple time points; STPIS mean change from baseline to 36 hours was as follows: Placebo (-7.84 (-14%) [95% CI -14.20 to -1.47]; p<0.0001), Treatment 1 (-42.41 (-75%)[95% CI -48.30 to -36.52]; p<0.0001), Treatment 2 (-38.60 (-68%)[95% CI -46.64 to -31.56]; p<0.0001), and Treatment 3 (-44.19 (-79%) [95% CI -52.11to -36.27]; p<0.0001). In repeated measure within group analysis all treatments significantly reduced cold symptom severity (MJS) from Days 1-2. Results were as follows: Treatment 1 (-2.26 (-38%) [95% CI -3.04 --1.47] p<0.0001), Treatment 2 (-3.81 (-53%) [95% CI -4.82 - -2.80] p<0.0001), Treatment 3 (-4.49 (-69%) [95% CI -5.62- -3.57]; p<0.0001). As a result of this study, we conclude that supporting upper respiratory epithelia and reducing COX-mediated inflammation may be used to effectively treat common cold symptoms. Trial registration Identifier: Posted 30/10/2023

Combination Treatment with High-Dose Vitamin C and Alpha-Tocopherol does not Enhance Respiratory-Tract Lining Fluid Vitamin C Levels in Asthmatics

Gamma Tocopherol-Enriched Supplement Reduces Sputum Eosinophilia and Endotoxin-Induced Sputum Neutrophilia in Volunteers with Asthma.

Effects of aerobic exercise and vitamin C supplementation on rhinitis symptoms in allergic rhinitis patients.

Intravenous vitamin C in the treatment of allergies: an interim subgroup analysis of a long-term observational study

Study of vitamin C therapy in allergic rhinitis

Vitamin E Prevents NRF2 Suppression by Allergens in Asthmatic Alveolar Macrophages in Vivo.

Interaction of vitamin E isoforms on asthma and allergic airway disease

Combination of High-Dose Parenteral Ascorbate (vitamin C) and Alpha-Lipoic Acid Failed to Enhance Tumor-Inhibitory Effect but Increased Toxicity in Preclinical Cancer Models

Comparable Function of γ-Tocopherols in Asthma Remission by Affecting Eotaxin and IL-4

Effects of Gamma-Tocopherol Supplementation on Thrombotic Risk Factors

A 12 week double-blind randomised controlled trial investigating the effect of dietary supplementation with 5000 IU/day (125 μg/day) vitamin D in adults with asthma, led to an improvement in the lung function parameter - FEV1:FVC ratio

New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine

A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity

A pilot randomized clinical trial of γ-tocopherol supplementation on wood smoke-induced neutrophilic and eosinophilic airway inflammation

Increased oxidative stress and altered antioxidants status in patients with chronic allergic rhinitis

Oxidative stress status and plasma trace elements in patients with asthma or allergic rhinitis

The effect of different treatment modalities on oxidative stress in COPD

Topical Vitamin D May Modulate Human Sinonasal Mucosal Responses to House Dust Mite Antigen

Supporting Respiratory Epithelia and Lowering Inflammation to Effectively Treat Common Cold Symptoms: A Randomized Controlled Trial

The effects of vitamin D supplementation on inflammatory biomarkers in patients with asthma: a systematic review and meta-analysis of randomized controlled trials

Associations of Serum Vitamin A and E Concentrations with Pulmonary Function Parameters and Chronic Obstructive Pulmonary Disease